KRAS and neoplasm: It is likely that the 0.26% KRAS G12V mutation detected in the plasma ctDNA of P6 already reflected the presence of the same KRAS mutation in tumor tissue at the time of blood sampling, and this mutation contributed to the resistance to anti-EGFR therapy because it was detected 7 months later in the more advanced tumor.